Exclusive License Agreement for ALT-B4
AstraZeneca has signed an exclusive license agreement with Alteogen Inc. for ALT-B4, a novel hyaluronidase powered by Hybrozyme™ platform technology. Under this agreement, AstraZeneca gains global rights to use ALT-B4 to develop and commercialize subcutaneous formulations for multiple oncology treatments. Alteogen will supply ALT-B4 for both clinical and commercial use.
Advantages of Subcutaneous Formulations
Subcutaneous drug delivery offers significant benefits, including reduced administration time, improving convenience for patients, healthcare providers, and hospital systems. This shift could enhance patient experience and optimize clinical workflows.
Commitment to Innovation in Cancer Care
As per the Astrazeneca press release, Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, emphasized the company’s dedication to improving cancer treatments. “We are committed to developing innovative medicines and finding more convenient delivery methods. This collaboration with Alteogen will help us introduce new subcutaneous options that could transform cancer care.”
Alteogen’s Vision for Hybrozyme™ Technology
Dr. Soon Jae Park, CEO of Alteogen, expressed enthusiasm about the partnership. “We are excited to expand our Hybrozyme™ Technology through this collaboration with AstraZeneca. Together, we aim to develop advanced subcutaneous cancer treatments that better serve patients.”
This collaboration marks a significant step toward improving cancer treatment accessibility and patient comfort through advanced drug delivery systems.